Thomas J. Sayers - Concepedia

Author

Thomas J. Sayers

Science Applications International Corporation (United States)

Also Known As

Duafalia Dudimah, Leslie A. A. Gunatilaka, T J Sayers, T SAYERS, T Sayers, T. J. Sayers, T. Sayers, T.J Sayers, T.J. Sayers, THOMAS J. SAYERS

188

Publications

7.3K

Citations

H-Index

135

Concepts

All Affiliations

Science Applications International Corporation (United States)Frederick National Laboratory for Cancer Research National Cancer Institute Center for Cancer Research Leidos (United States)

About

Thomas J. Sayers is an author at Science Applications International Corporation (United States) specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	39	2.6K
2	Natural Sciences	8	8	435
3	Biochemistry	5	5	173
4	Allergy	4	4	262
5	Health Sciences	1	1	61

Thomas J. Sayers

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Alpha and β chemokines induce NK cell migration and enhance NK-mediated cytolysis Dennis D. Taub, Thomas J. Sayers, C R Carter, The Journal of Immunology	1995	452
Sensitization of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs Ancy D. Nalli, Lauren E. Brown, Cheryl L. Thomas, Scientific Reports	2018	297
Identification of Human Neutrophil-derived Cathepsin G and Azurocidin/CAP37 as Chemoattractants for Mononuclear Cells and Neutrophils Oleg Chertov, Hirotsugu Ueda, Luo Ling Xu, The Journal of Experimental Medicine	1997	261
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib Kai Sun, Angela Panoskaltsis‐Mortari, Matthew J. O’Shaughnessy, Proceedings of the National Academy of Sciences Cell TherapyGvhd-associated ParametersImmunologyProteasome Inhibitor BortezomibPathology	2004	241
NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype Erik Ames, Robert J. Canter, Steven K. Grossenbacher, The Journal of Immunology Cell TherapyNatural Killer CellsCancer ImmunosurveillanceMedicineImmunology	2015	234
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP Thomas J. Sayers, Alan D. Brooks, Crystal Y. Koh, Blood	2003	228
Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy Kazuyoshi Takeda, Noriko Yamaguchi, Hisaya Akiba, The Journal of Experimental Medicine	2004	204
The Trophic Action of IL-7 on Pro-T Cells: Inhibition of Apoptosis of Pro-T1, -T2, and -T3 Cells Correlates with Bcl-2 and Bax Levels and Is Independent of Fas and p53 Pathways Kyungjae Kim, Chong‐Kil Lee, Thomas J. Sayers, The Journal of Immunology Lymphocyte DevelopmentT-regulatory CellApoptosisImmunologyImmune Regulation	1998	180
Unlocking the secrets of cytotoxic granule proteins Mark J. Smyth, Janice M. Kelly, Vivien R. Sutton, Journal of Leukocyte Biology Protein SecretionApoptosisImmunologyCell DeathPathology	2001	175
NKG2D Recognition and Perforin Effector Function Mediate Effective Cytokine Immunotherapy of Cancer Mark J. Smyth, Jeremy B. Swann, Janice M. Kelly, The Journal of Experimental Medicine Tumor BiologyCytokineCancer ImmunosurveillanceNkg2d RecognitionMedicine	2004	167

Page 1